相似文献
1
The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information.
Leuk Res. 1990;14(5):395-9. doi: 10.1016/0145-2126(90)90024-4.
2
Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model.
Transplantation. 1986 May;41(5):644-7. doi: 10.1097/00007890-198605000-00018.
3
Thalidomide for treatment of graft-versus-host disease.
Bone Marrow Transplant. 1988 Sep;3(5):393-8.
4
The use of thalidomide in chronic refractory graft versus host disease.
Neth J Med. 2001 Aug;59(2):45-9. doi: 10.1016/s0300-2977(01)00133-4.
5
Graft-versus-host disease.
Curr Opin Oncol. 1994 Jul;6(4):358-64. doi: 10.1097/00001622-199407000-00006.
6
Thalidomide for chronic GVHD.
Bone Marrow Transplant. 1998 Nov;22(9):933-4. doi: 10.1038/sj.bmt.1701467.
7
Thalidomide for the treatment of chronic graft-versus-host disease.
N Engl J Med. 1992 Apr 16;326(16):1055-8. doi: 10.1056/NEJM199204163261604.
8
Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature.
Pediatrics. 1999 Apr;103(4):e44. doi: 10.1542/peds.103.4.e44.
9
Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease.
Leuk Lymphoma. 2003 Jul;44(7):1141-6. doi: 10.1080/1042819031000079096.
10
Response to thalidomide therapy in refractory chronic graft-versus-host disease.
Bone Marrow Transplant. 2000 Oct;26(8):865-9. doi: 10.1038/sj.bmt.1702626.
引用本文的文献
1
Management of graft-versus-host disease in paediatric bone marrow transplant recipients.
Paediatr Drugs. 2000 Jan-Feb;2(1):29-55. doi: 10.2165/00148581-200002010-00004.
2
Thalidomide: rationale for renewed use in immunological disorders.
Drug Saf. 1995 Jun;12(6):364-9. doi: 10.2165/00002018-199512060-00002.
3
Oral complications of cancer.
BMJ. 1991 Apr 6;302(6780):848.
4
Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.
Drug Saf. 1992 Mar-Apr;7(2):116-34. doi: 10.2165/00002018-199207020-00004.
本文引用的文献
1
[Thalidomide embryopathy].
Dtsch Med Wochenschr. 1962 Jun 15;87:1232-42. doi: 10.1055/s-0028-1111892.
2
PROLONGATION OF SKIN HOMOGRAFT SURVIVAL BY THALIDOMIDE.
Br Med J. 1965 Sep 18;2(5463):687-9. doi: 10.1136/bmj.2.5463.687.
3
THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS.
Clin Pharmacol Ther. 1965 May-Jun;6:303-6. doi: 10.1002/cpt196563303.
4
Marrow transplants in lethally irradiated dogs given methotrexate.
Blood. 1962 Feb;19:217-28.
5
Alteration of homograft reaction by A-methopterin in lethally irradiated mice treated with homologous marrow.
Proc Soc Exp Biol Med. 1958 Dec;99(3):651-3. doi: 10.3181/00379727-99-24450.
6
Response of graft versus host disease to high doses of methyl prednisolone.
Clin Lab Haematol. 1981;3(1):19-26. doi: 10.1111/j.1365-2257.1981.tb01305.x.
7
Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions.
J Am Acad Dermatol. 1982 Sep;7(3):317-23. doi: 10.1016/s0190-9622(82)70118-5.
8
Use of cyclosporin A (CsA) in a rat model of allogeneic marrow transplantation.
Haematol Blood Transfus. 1980;25:241-53. doi: 10.1007/978-3-642-67319-1_20.
9
10
Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite.
Proc Natl Acad Sci U S A. 1981 Apr;78(4):2545-8. doi: 10.1073/pnas.78.4.2545.
Zotero 插件